PAC8 is a venture capital firm that invests in disruptive technology platforms and healthcare companies. PAC8 focuses on seed stage investments, primarily in the US market.

PAC8

Pacific 8 Ventures is a venture capital firm that invests at the nexus of cutting-edge technology platforms and biology/medicine. We focus on early-stage startups.

Our investments consist of high-performing companies in the area of synthetic biology, gene therapy, CRISPR, machine learning/artificial intelligence, digital therapeutics, and more.

Founders appreciate that we can be more than just a capital partner but also a strategic partner for market access given our LP and advisor base consists of groups that own and operate hospitals, clinics, health insurance, and life insurance companies.

Pacific 8 Ventures

Congratulations to Ashley Zehnder and the Fauna Bio team on being chosen from hundreds of nominees for Fierce Biotech’s 2024 Fierce 15 List! This fantastic recognition shines a spotlight on their innovative approach in harnessing the power of biology from other species to advance human health. Keep up the amazing work!

Congratulations to Empirical Health for launching Empirical 2.0, which integrates biometric data with medical AI to provide personalized healthcare!!!

Huge congratulations to Oguzhan Atay, PhD, David Tsao, and the exceptional BillionToOne team on securing $130 million in an oversubscribed Series D funding round. This funding will further revolutionize the prenatal screening and oncology diagnostics landscape.

We’re incredibly proud of the team and thrilled to have partnered with them on this exciting journey!!!

Congratulations to Trevor Martin, Janice Chen, Lucas Harrington and the Mammoth Biosciences team for securing another major gene-editing collaboration with Regeneron! This $100M upfront agreement is poised to develop in-vivo CRISPR-based gene editing therapies, broadening their potential to target various tissues beyond the liver. What an incredible achievement!!!

PAC8

COM:PAC8

PAC8